These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 37796692)

  • 1. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.
    Zhou S; Sun H; Choi SI; Yin J
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):206. PubMed ID: 37796692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future.
    Li L; Zhu X; Qian Y; Yuan X; Ding Y; Hu D; He X; Wu Y
    Front Immunol; 2020; 11():594271. PubMed ID: 33224149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future.
    Lin YJ; Mashouf LA; Lim M
    Front Immunol; 2022; 13():817296. PubMed ID: 35265074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-T Cells Therapy in Glioblastoma: A Systematic Review on Molecular Targets and Treatment Strategies.
    Agosti E; Garaba A; Antonietti S; Ius T; Fontanella MM; Zeppieri M; Panciani PP
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment.
    Feldman L; Brown C; Badie B
    Neurosurgery; 2021 May; 88(6):1056-1064. PubMed ID: 33575786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.
    Bagley SJ; Desai AS; Linette GP; June CH; O'Rourke DM
    Neuro Oncol; 2018 Oct; 20(11):1429-1438. PubMed ID: 29509936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR T-Cell Therapies in Glioblastoma: A First Look.
    Migliorini D; Dietrich PY; Stupp R; Linette GP; Posey AD; June CH
    Clin Cancer Res; 2018 Feb; 24(3):535-540. PubMed ID: 29158268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The update of chimeric antigen receptor-T cells therapy in glioblastoma.
    Chou CJ; Lin CF; Chen YW; Huang PI; Yang YP; Wang ML; Hung KF; Lee YY
    J Chin Med Assoc; 2020 May; 83(5):442-445. PubMed ID: 32217989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
    Zhang P; Zhang Y; Ji N
    Front Immunol; 2022; 13():927132. PubMed ID: 35874698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.
    Choi BD; Maus MV; June CH; Sampson JH
    Clin Cancer Res; 2019 Apr; 25(7):2042-2048. PubMed ID: 30446589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy.
    Salinas RD; Durgin JS; O'Rourke DM
    CNS Drugs; 2020 Feb; 34(2):127-145. PubMed ID: 31916100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
    Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
    Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
    Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
    Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.
    Ren PP; Li M; Li TF; Han SY
    Curr Pharm Des; 2017; 23(14):2113-2116. PubMed ID: 28302023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.
    Verma A; Rafiq S
    Cancer Treat Res; 2022; 183():161-184. PubMed ID: 35551659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?
    Prinzing BL; Gottschalk SM; Krenciute G
    Expert Rev Anticancer Ther; 2018 May; 18(5):451-461. PubMed ID: 29533108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
    Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
    Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing CAR-T Therapy for Glioblastoma.
    Tang OY; Binder ZA; O'Rourke DM; Bagley SJ
    Mol Diagn Ther; 2023 Nov; 27(6):643-660. PubMed ID: 37700186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
    Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.